Kawasaki disease: Insights into pathogenesis and approaches to treatment

Nature Reviews Rheumatology

Volumn 11, Issue 8, 2015, Pages 475-482

  Shulman, Stanford T ^a   Rowley, Anne H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ARTERITIS; CORONARY ARTERY DISEASE; DISEASE MODEL; DISEASE PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOPATHOLOGY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THEORETICAL MODEL; TREATMENT PLANNING; VASCULAR DISEASE; GENETICS; IMMUNOLOGY;

HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84938424351     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.54     Document Type: Review

References (73)

1. Kawasaki, T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [Japanese]. Arerugi 16, 178-222 (1967).
2. Amano, S., Hazama, F. & Hamashima, Y. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ. J. 43, 633-643 (1979).
3. Yanagisawa, M., Kobayashi, N. & Matsuya, S. Myocardial infarction due to coronary thromboarteritis, following acute febrile mucocutaneous lymph node syndrome (MLNS) in an infant. Pediatrics 54, 277-280 (1974).
4. Kato, H., Koike, S., Yamamoto, M., Ito, Y. & Yano, E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J. Pediatr. 86, 892-898 (1975).
5. Amano, S., Hazama, F. & Hamashima, Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ. J. 43, 741-748 (1979).
6. Taubert, K. A., Rowley, A. H. & Shulman, S. T. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr. Infect. Dis. J. 13, 704-708 (1994).
7. Yanagawa, H., et al. A nationwide incidence survey of Kawasaki disease in 1985-1986 in Japan. J. Infect. Dis. 158, 1296-1301 (1988).
8. Rodó, X., et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc. Natl Acad. Sci. USA 111, 7952-7957 (2014).
9. Yim, D., Curtis, N., Cheung, M. & Burgner, D. Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J. Pediatr. Child Health 49, 704-708 (2013).
10. Onouchi, Y. Genetics of Kawasaki disease: what we know and dont know. Circ. J. 76, 1581-1586 (2012).
11. Brogan, P. A. Shah, V., Clarke, L. A., Dillon, M. J., & Klein, N. T cell activation profiles in Kawasaki syndrome. Clin. Exp. Immunol. 151, 267-274 (2008).
12. Rowley, A. H., Eckerley, C. A., Jack, H. M., Shulman, S. T. & Baker, S. C. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J. Immunol. 159, 5946-5955 (1997).
13. Rowley, A. H., et al. Cloning the arterial IgA antibody response during acute Kawasaki disease. J. Immunol. 175, 8386-8391 (2005).
14. Rowley, A. H., et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis. 182, 1183-1191 (2000).
15. Rowley, A. H., Shulman, S. T., Spike, B. T., Mask, C. A. & Baker, S. C. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J. Immunol. 166, 1334-1343 (2001).
16. Rowley, A. H., et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J. Infect. Dis. 192, 1757-1766 (2005).
17. Rowley, A. H., et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE 3, e1582 (2008).
18. Rowley, A. H., et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J. Infect. Dis. 190, 856-865 (2004).
19. Rowley, A. H., et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J. Infect. Dis. 203, 1021-1030 (2011).
20. Nielsen, H. B., et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 32, 822-828 (2014).
21. Nakamura, Y., et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J. Epidemiol. 3, 216-221 (2012).
22. Holman, R. C., et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007 Pediatr. Infect. Dis. J. 29, 483-488 (2010).
23. Holman, R. C., et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med. J. 69, 194-197 (2010).
24. Newburger, J. W., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110, 2747-2771 (2004).
25. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ. J. 78, 2521-2562 (2014).
26. Fujiwara, H. & Hamashima, Y. Pathology of the heart in Kawasaki disease. Pediatrics 61, 100-107 (1978).
27. Sasaguri, Y. & Kato, H. Regression of aneurysms in Kawasaki disease: a pathological study. J. Pediatr. 100, 225-231 (1982).
28. Orenstein, J. M., et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS ONE 7, e38998 (2012).
29. Kuijpers, T. W., et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics 112, 986-992 (2003).
30. Burke, A. P., et al. Fatal Kawasaki disease with coronary arteritis and no coronary aneurysms. Pediatrics 101 (Pt 1), 108-112 (1998).
31. Satoda, M., Tatsukawa, H. & Katoh, S. Images in cardiovascular medicine. Sudden death due to rupture of coronary aneurysm in a 26-year-old man. Circulation 97, 705-706 (1998).
32. Heaton, P. & Wilson, N. Fatal Kawasaki disease caused by early occlusive coronary artery disease. Arch. Dis. Child. 87, 145-146 (2002).
33. Ozawa, J., et al. Two cases of new coronary aneurysms that developed in the late period after Kawasaki disease. Pediatr. Cardiol. 34, 1992-1995 (2013).
34. Toyono, M., et al. Expanding coronary aneurysm in the late phase of Kawasaki disease. Pediatr. Int. 54, 155-158 (2012).
35. Tsuda, E., Kamiya, T., Ono, Y., Kimura, K. & Echigo, S. Dilated coronary arterial lesions in the late period after Kawasaki disease. Heart 91, 177-182 (2005).
36. Kobayashi, T., Sone, K., Shinohara, M., Kosuda, T. & Kobayashi, T. Images in cardiovascular medicine. Giant coronary aneurysm of Kawasaki disease developing during postacute phase. Circulation 98, 92-93 (1998).
37. Kawai, H., et al. Two cases with past Kawasaki disease developing acute myocardial infarction in their thirties, despite being regarded as at low risk for coronary events. Heart Vessels http://dx.doi.org/10.1007/s00380-014-0541-4.
38. Tsuda, E., Hanatani, A., Kurosaki, K., Naito, H. & Echigo, S. Two young adults who had acute coronary syndrome after regression of coronary aneurysms caused by Kawasaki disease in infancy. Pediatr. Cardiol. 27, 372-375 (2006).
39. Onouchi, Z., et al. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans. Angiology 46, 679-687 (1995).
40. Rosenkranz, M. E., et al. TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation 112, 2966-2973 (2005).
41. Lau, A. C., Duong, T. T., Ito, S., Wilson, G. J. & Yeung, R. S. M. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin. Exp. Immunol. 157, 300-309 (2009).
42. Takahashi, K., et al. Histopathologic features of murine systemic vasculitis caused by Candida albicans extract-an animal model of Kawasaki disease. Inflamm. Res. 53, 72-77 (2004).
43. Orenstein, J. M. & Rowley, A. H. An evaluation of the validity of the animal models of Kawasaki disease vasculopathy. Ultrastruct. Pathol. 38, 245-247 (2014).
44. Reindel, R., et al. Integrins α4 and αM, collagen1A1, and matrix metalloproteinase 7 are upregulated in acute Kawasaki disease vasculopathy. Pediatr. Res. 73, 332-336 (2013).
45. Reindel, R., et al. CD84 is markedly up-regulated in Kawasaki disease arteriopathy. Clin. Exp. Immunol. 177, 203-211 (2014).
46. Reindel, R., et al. Periostin is upregulated in coronary arteriopathy in Kawasaki disease and is a potential diagnostic biomarker. Pediatr. Infect. Dis. J. 33, 659-661 (2014).
47. Fujita, Y., et al. Kawasaki disease in families. Pediatrics 84, 666-669 (1989).
48. Uehara, R., Yashiro, M., Nakamura, Y. & Yanagawa, H. Kawasaki disease in parents and children. Acta Paediatr. 92, 694-697 (2003).
49. Park, Y. W., et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr. Int. 53, 36-39 (2011).
50. Huang, W. C., et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 123, e401-e405 (2009).
51. Onouchi, Y., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 40, 35-42 (2008).
52. Kuo, H. C., et al. Single nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease. PLoS ONE 12, e91118 (2014).
53. Onouchi, Y., et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum. Mol. Genet. 19, 2898-2906 (2010).
54. Kuo, H. C., et al. CASP3 gene single nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J. Hum. Genet. 56, 161-165 (2011).
55. Onouchi, Y., et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat. Genet. 44, 517-521 (2012).
56. Lee, Y. C., et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat. Genet. 44, 522-525 (2012).
57. Weng, K. P., et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ. J. 74, 544-551 (2010).
58. Onouchi, Y., et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 13, 52-59 (2013).
59. Newburger, J. W., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315, 341-347 (1986).
60. Newburger, J. W., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324, 1633-1639 (1991).
61. Furusho, K., et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2, 1055-1058 (1984).
62. Terai, M. & Shulman, S. T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 131, 888-893 (1997).
63. Newburger, J. W., et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 356, 663-675 (2007).
64. Ogata, S., et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129, e17-e23 (2012).
65. Inoue, Y., et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J. Pediatr. 149, 336-341 (2006).
66. Kobayashi, T., et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379, 1613-1620 (2012).
67. Sleeper, L. A., et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J. Pediatr. 158, 831.e3-835.e3 (2011).
68. Tremoulet, A. H., et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383, 1731-1738 (2014).
69. Horosaki, T., et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr. Int. 54, 99-103 (2012).
70. Lee, T. J., Kim, K. H., Chun, J.-K. & Kim, D. S. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med. J. 49, 714-718 (2008).
71. Tremoulet, A. H., et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 161, 506.e1-512.e1 (2012).
72. Shafferman, A., Birmingham, J. D. & Cron, R. Q. High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr. Rheumatol. Online J. 12, 26 (2014).
73. Niedra, E., Chahal, N., Manlhiot, C., Yeung, R. S. & McCrindle, B. W. Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. Pediatr. Cardiol. 35, 89-92 (2014).